Search

Displaying results 4581 - 4590 of 10000 in total
  1. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA. … [A182039,A182045] Newer generations of DNA minor groove binding agents can more specifically recognize base pair sequences.[A182051]

  2. Drug

    Benziodarone

    go.drugbank.com/drugs/DB13277
    ApprovedWithdrawn

    Benziodarone is a uricostatic and a uricosuric agent which is sold also under the name Amplivex-Labaz. It is used in the treatment of gout [A175630]. … It was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].

    Categories: Vasodilators Used in Cardiac Diseases
  3. Drug

    Fleroxacin

    go.drugbank.com/drugs/DB04576
    Experimental

    Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.[A39048]

    Categories: Topoisomerase II Inhibitors
  4. Drug

    Atractylodes japonica root oil

    go.drugbank.com/drugs/DB11270
    ApprovedWithdrawn

    It is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation. … Atractylodes japonica root oil is obtained from the roots of Atractylodes japonica, which is a herb native to eastern Asia.

  5. Drug

    Benznidazole

    go.drugbank.com/drugs/DB11989
    ApprovedInvestigational

    [L939] It is the first treatment made available in the United States for Chagas disease. … Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.

  6. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    It is completely devoid of animal-derived components. FDA approved on March 6, 2012. … Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use.

  7. Drug

    Pipotiazine

    go.drugbank.com/drugs/DB01621
    ApprovedInvestigationalWithdrawn

    However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. … Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics.

    Categories: Dopamine D2 Receptor Antagonists, Serotonin Receptor Antagonists
  8. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis. … The cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April 2023.

  9. Drug

    Aluminum zirconium pentachlorohydrate

    go.drugbank.com/drugs/DB11147
    Approved

    Aluminum zirconium pentachlorohydrate is a common active ingredient in personal care products as an antiperspirant agent. … Its main mechanism of action is through blocking the pores via formation of polymer complex and preventing sweat from leaving the body.

  10. Drug

    Buserelin

    go.drugbank.com/drugs/DB06719
    ApprovedInvestigational

    It is used in prostate cancer treatment. … Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR).